Steven Cohen 4 D Molecular Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$9.76 - $21.25 $364,594 - $793,815	-37,356 Reduced 8.24%	416,020 $8.43 Million
Q3 2023 Nov 14, 2023	BUY	$12.64 - $19.76 $1.04 Million - $1.63 Million	82,489 Added 22.24%	453,376 $5.77 Million
Q2 2023 Aug 14, 2023	BUY	$15.16 - $23.26 $2.46 Million - $3.77 Million	161,987 Added 77.54%	370,887 $6.7 Million
Q1 2023 May 15, 2023	BUY	$15.45 - $23.19 $1.08 Million - $1.61 Million	69,600 Added 49.96%	208,900 $3.59 Million
Q4 2022 Feb 14, 2023	SELL	$6.85 - $25.46 $1.09 Million - $4.07 Million	-159,700 Reduced 53.41%	139,300 $3.09 Million

Q3 2022 Nov 14, 2022	BUY	$6.96 - $11.48 $2.08 Million - $3.43 Million	299,000 New	299,000 $2.4 Million

157

50.3M

718K

370K

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $666M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.